ÂÜÀòÂÒÂ×

Alexandra Sevko is a consultant in translational research at Resilient Collective, specializing in biotech and early-phase clinical trial support in cancer immunotherapy since November 2024. Prior experience includes serving as Director of Translational Research at Prokarium, where leadership in clinical trial strategies was demonstrated from September 2021 to November 2024. Alexandra held the role of Principal Scientist at Adaptimmune from August 2015 to August 2021, managing projects on next-generation therapies and contributing to a patent and multiple publications. Earlier positions included research roles at University College London and Imperial College London with a focus on TRAIL signaling in the tumor microenvironment. Research at the German Cancer Research Center involved investigating chemoimmunomodulation for melanoma treatment. Alexandra earned a Ph.D. in Biological Sciences (Oncology) from the RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine and has a background in clinical laboratory diagnostics.